Literature DB >> 31983465

Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team.

Francesco Pelliccia1, Ottavio Alfieri2, Paolo Calabrò3, Franco Cecchi4, Paolo Ferrazzi5, Felice Gragnano3, Juan Pablo Kaski6, Giuseppe Limongelli7, Martin Maron8, Claudio Rapezzi9, Hubert Seggewiss10, Magdi H Yacoub11, Iacopo Olivotto12.   

Abstract

Patients with hypertrophic cardiomyopathy (HCM) exhibit a variable phenotype with ventricular hypertrophy as the cardinal manifestation and left ventricular (LV) outflow tract obstruction (LVOTO) as a key pathophysiologic determinant. Patients with severe LVOTO usually present with exertional dyspnea, exertional syncope, and heart failure symptoms, while successful relief of LVOTO by pharmacological or invasive interventions leads to a dramatic improvement in clinical status. Proper management of obstructive HCM remains challenging and poses numerous clinical dilemmas. Since the development of surgical myectomy over half a century ago, progress in the management of LVOTO in HCM has paralleled technological advances in genetic testing, cardiac imaging, arrhythmic prophylaxis, cardiac surgery and interventional cardiology. These changes have been incorporated in dedicated scientific guidelines on both sides of the Atlantic. However, either the 2011 American guidelines or the 2014 European guidelines remain largely based on expert consensus for lack of recommendations with level of evidence A regarding any of the treatment options commonly employed in HCM. Consequently, management of obstructive HCM patients remains largely subjective and dependent on clinical judgment, local expertise, and patient preference. Following the trend that has emerged for other cardiac diseases amenable to invasive interventions, adequate evaluation and management of obstruction in HCM today requires a multidisciplinary team capable of optimizing referral, choosing the best available options, minimizing complications and ensuring state-of-the-art results. The concept of an HCM Heart Team is coming of age. This review aims to provide an update of available pharmacologic and invasive options for the management of LVOTO in HCM, either in adulthood or in childhood, highlighting areas for multidisciplinary integration and future development.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alcohol septal ablation; Gradient; Hypertrophic cardiomyopathy; Left ventricular outflow tract; Myectomy; Obstruction

Mesh:

Year:  2020        PMID: 31983465     DOI: 10.1016/j.ijcard.2020.01.021

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Hypertrophic obstructive cardiomyopathy complicated with acute myocardial infarction and diffuse fibrosis: surgery or not?

Authors:  Yunhong Wang; Xuemei Zhao; Mei Zhai; Yan Huang; Qiong Zhou; Yuhui Zhang; Yi Mao; Jian Zhang
Journal:  BMC Cardiovasc Disord       Date:  2022-04-13       Impact factor: 2.298

2.  COVID-19 pandemia and inherited cardiomyopathies and channelopathies: a short term and long term perspective.

Authors:  Giuseppe Limongelli; Lia Crotti
Journal:  Orphanet J Rare Dis       Date:  2020-06-22       Impact factor: 4.123

3.  Age-related survival after alcohol septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  Angelika Batzner; Diaa Aicha; Barbara Pfeiffer; Anna Neugebauer; Hubert Seggewiss
Journal:  ESC Heart Fail       Date:  2021-12-13

Review 4.  Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy.

Authors:  F Pelliccia; H Seggewiss; F Cecchi; P Calabrò; G Limongelli; O Alfieri; P Ferrazzi; M H Yacoub; I Olivotto
Journal:  Curr Cardiol Rep       Date:  2021-10-01       Impact factor: 2.931

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.